Pharmaceutical
| Mon 25 May 2026
Beijing, May 25 -- Tyvenebio Inc has applied Chinese patent for Dual Inhibitor Kallikrein Antibodies and Uses Thereof. Dowe Jennifer L, Cappelli Alan, Zorn Leonard, Entova Sonia, Nordic Christopher, Carvino Jenna, Boland Todd, Tang Ye, Herring Brantley, Lunde Bradley and Sharkey Nathan developed it.
The patent application num..